2026-W46 · Nov 9–Nov 15 · Company · Profile · published
AbbVie company profile · business segments · history · financial snapshot · S&P 500 rank #20 · 艾伯維公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | ABBV (NYSE) |
| Company | AbbVie Inc. |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #20 · 0.71% (Oct 21, 2026) |
| Sector rank (by market cap) | #3 in Health Care (Oct 16, 2026) |
| Headquarters | North Chicago, Illinois (1 North Waukegan Road) |
| Founded | January 1, 2013 (spin-off from Abbott Laboratories; incorporated in Delaware April 10, 2012) |
| CEO | Robert A. Michael (chairman & CEO; CEO since July 1, 2024, chairman since July 1, 2025) |
| Employees | ~57,000 in over 70 countries (Dec 31, 2025, FY2025 10-K) |
| Market cap | $504B (assignment baseline) |
| SEC filings | EDGAR — CIK 0001551152 |
WHAT IT DOES
AbbVie Inc. is a global biopharmaceutical company headquartered in North Chicago, Illinois — in the company's own words, "the discovery, development, manufacturing and sale of a broad line of therapies that address some of the world's most complex and serious diseases" (FY2025 10-K). Its one-line model: develop or acquire patent-protected branded medicines, then sell them worldwide through wholesalers, distributors, government agencies and specialty pharmacies — and, for aesthetics, directly to physicians and other licensed providers. Immunology is the engine: nearly half of FY2025's record $61.160B of net revenues came from the immunology portfolio.
AbbVie reports as a single global business segment; management discusses revenue by therapeutic portfolio. Immunology ($30.406B, +14.0%) is Skyrizi ($17.562B, +49.9%) and Rinvoq ($8.304B, +39.1%) — the two drugs replacing Humira ($4.540B, −49.5%) as it falls off the industry's largest patent cliff. Neuroscience ($10.767B, +19.6%) is the fastest-growing therapeutic area: Vraylar ($3.621B), Botox Therapeutic ($3.769B), Ubrelvy ($1.271B), Qulipta ($1.036B) and Vyalev ($482M, up from $99M in 2024). Oncology ($6.655B, +1.5%) is Venclexta ($2.792B, +8.1%) offsetting Imbruvica's decline ($2.869B, −14.3%), plus the Elahere antibody-drug conjugate ($690M, +44.0%). Aesthetics ($4.860B, −6.1%) is Botox Cosmetic ($2.602B) and the Juvederm Collection ($993M, −15.6%), under consumer pressure. Eye Care ($2.109B, −5.9%) and Other Key Products ($3.736B, +2.4% — Creon $1.512B, Mavyret $1.317B, Linzess $907M) round out the mix.
The business model is a patent-cliff treadmill run at scale: GAAP R&D of $9.096B plus adjusted R&D investment of $13.8B in 2025, and more than $5B of 2025 business development (a novel psychedelic compound for major depressive disorder, in-vivo CAR-T, an siRNA platform and an amylin analog for obesity) to rebuild the pipeline as Humira fades. The 2020 Allergan acquisition diversified the revenue base into aesthetics and eye care, and the Immunogen, Cerevel, Aliada and Capstan deals (with the $10.9B Apogee acquisition announced in June 2026) keep the oncology and neuroscience pipelines fed. Strong cash generation — $19.030B of operating cash flow in 2025 — funds one of health care's longest dividend streaks ($11.657B paid out in 2025).
BUSINESS SEGMENTS — FY2025 NET REVENUES BY THERAPEUTIC PORTFOLIO
| Portfolio | Net revenue | Share | YoY | Key products |
|---|---|---|---|---|
| Immunology | $30.406B | 49.7% | +14.0% | Skyrizi $17.56B · Rinvoq $8.30B · Humira $4.54B |
| Neuroscience | $10.767B | 17.6% | +19.6% | Vraylar $3.62B · Botox Therapeutic $3.77B · Ubrelvy $1.27B · Qulipta $1.04B |
| Oncology | $6.655B | 10.9% | +1.5% | Venclexta $2.79B · Imbruvica $2.87B · Elahere $0.69B · Epkinly $0.27B |
| Aesthetics | $4.860B | 7.9% | −6.1% | Botox Cosmetic $2.60B · Juvederm Collection $0.99B |
| Other key products | $3.736B | 6.1% | +2.4% | Creon $1.51B · Mavyret $1.32B · Linzess $0.91B |
| Eye care | $2.109B | 3.4% | −5.9% | Ozurdex $0.49B · Lumigan/Ganfort $0.41B |
| All other | $2.627B | 4.3% | n/m | — |
| Total net revenues | $61.160B | 100% | +8.6% | — |
Immunology is the post-Humira growth engine. Skyrizi and Rinvoq combined for $25.866B in 2025 — up $8.2B year over year — while Humira fell from $14.404B in 2023 to $4.540B; CEO Robert Michael noted "close to $16B in U.S. Humira erosion since" loss of exclusivity, and management targets more than $31B of combined Skyrizi/Rinvoq sales by 2027.
Neuroscience is the fastest-growing therapeutic area (+19.6%), anchored by Vraylar and Botox Therapeutic and extended by the migraine pair Ubrelvy/Qulipta ($2.307B combined) and the Parkinson's launch Vyalev. The 2024 Cerevel acquisition ($8.7B) deepened the neuroscience pipeline; management expects the Parkinson's franchise (Vyalev plus tavapadon) to exceed $5B in peak sales.
Oncology is in transition: Venclexta (+8.1%) and the Elahere antibody-drug conjugate (+44.0%) are growing while Imbruvica (−14.3%) faces IRA Medicare price pressure and next-generation BTK competition. The 2024 ImmunoGen acquisition ($10.1B) brought Elahere into the fold.
Aesthetics and Eye Care are the Allergan legacy — cash-generative but cyclical (aesthetics −6.1% on consumer softness) and exposed to generics (eye care −5.9%, led by Restasis pressure).
HISTORY
| Year | Milestone |
|---|---|
| 2012 | April 10 — AbbVie Inc. incorporated in Delaware (FY2025 10-K, Note 1) |
| 2013 | January 1 — Spin-off from Abbott Laboratories completed; AbbVie becomes an independent publicly-traded company, inheriting Humira (FY2025 10-K, Note 1) |
| 2015 | Acquires Pharmacyclics for $21B — bringing Imbruvica, AbbVie's first big oncology blockbuster (company IR) |
| 2019–20 | Allergan acquisition announced (June 2019) and closed May 8, 2020 for $63B — adding Botox, the Juvederm Collection and the eye-care franchise (company IR) |
| 2023 | First U.S. biosimilar competition for Humira (January) — "the pharmaceutical industry's largest patent cliff in history" (10-K shareholder letter); Humira U.S. sales begin their steep erosion |
| 2024 | ImmunoGen acquisition closed (February, $10.1B) — Elahere antibody-drug conjugate franchise; Cerevel Therapeutics acquisition closed (August, $8.7B) — neuroscience pipeline; Aliada Therapeutics acquired (December, $1.4B) — Alzheimer's antibody |
| 2024 | July 1 — Robert A. Michael becomes chief executive officer; Vyalev approved by the FDA for advanced Parkinson's disease (October) |
| 2025 | Key approvals: Rinvoq for giant cell arteritis, Emrelis (telisotuzumab vedotin) for non-squamous non-small cell lung cancer, Epkinly for second-line follicular lymphoma (10-K shareholder letter); Capstan Therapeutics acquired ($2.1B) — in-vivo CAR-T platform; $906M upfront for Gilgamesh's psychedelic MDD compound |
| 2025 | July 1 — Michael becomes chairman of the board; Rick Gonzalez retires as executive chairman (10-K lead-director letter) |
| 2026 | June 22 (announcement) — Definitive agreement to acquire Apogee Therapeutics for $10.9B in equity value, deepening the immunology portfolio (long-acting biologics); expected to close in Q3 2026 (Q2 2026 earnings release) |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total net revenues | $61.160B (+8.6% reported / +8.5% operational YoY; FY2024 $56.334B) |
| Cost of products sold | $18.204B (+7.7% YoY) |
| Gross profit / gross margin | $42.956B / 70.2% (computed from reported figures) |
| SG&A | $14.010B (−5.0% YoY) |
| R&D (GAAP) | $9.096B (−28.9% YoY; FY2024 included large Cerevel/ImmunoGen charges) |
| Acquired IPR&D and milestones | $5.016B |
| Operating earnings / operating margin | $15.075B / 24.6% (computed from reported figures) |
| Adjusted R&D investment (non-GAAP) | $13.8B (10-K shareholder letter) |
| Net earnings | $4.233B (attributable to AbbVie $4.226B); net margin 6.9% (computed) |
| Diluted EPS (GAAP) | $2.36 (vs $2.39 in FY2024) |
| Adjusted diluted EPS (non-GAAP) | $10.00 (−1.2% YoY; incl. −$2.76/share of acquired IPR&D and milestones) |
| Operating cash flow | $19.030B |
| Capital expenditures | $1.214B |
| Free cash flow | $17.816B (operating cash flow − capex; computed) |
| Total debt | $64.997B (long-term debt & finance lease obligations, Dec 31, 2025) |
| Cash and equivalents | $5.229B (Dec 31, 2025) |
| Net debt | $59.768B (total debt − cash; computed) |
| Dividends paid | $11.657B; quarterly dividend raised 5.5% to $1.73 (Oct 31, 2025; payable Feb 17, 2026; annualized $6.92) |
| Latest quarter (Q2 2026, ended Jun 30, 2026) | Net revenues $16.990B (+10.2% YoY) · GAAP diluted EPS $2.03 (+290.4%) · Adjusted diluted EPS $3.65 (+22.9%; incl. −$0.17/share IPR&D) · Adjusted gross margin 84.7% · Adjusted operating margin 48.3% · FY2026 guidance: net revenues ~$67.6B, adjusted diluted EPS $13.87–14.07 (incl. $0.14 of Apogee dilution) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
AbbVie is the index's #20 constituent at a 0.71% weight — a 1% move in ABBV moves the S&P 500 by roughly 0.7 basis points — and the #3 Health Care name by market cap. It is the index's purest large-cap biotech bellwether (GICS sub-industry Biotechnology), sitting alongside Johnson & Johnson, Eli Lilly and UnitedHealth as one of the sector's anchor weights in XLV.
For market-structure watchers, ABBV is the sector's read-through on three themes: the pace of biosimilar erosion after the industry's largest patent cliff (Humira), the pricing power of next-generation immunology biologics (Skyrizi/Rinvoq), and the real-world impact of IRA Medicare drug-price negotiation (Imbruvica). With 54 consecutive annual dividend increases, it is also the income anchor of Health Care — its $11.657B of 2025 dividends were comfortably covered by $17.8B of free cash flow.
SOURCES & METHODOLOGY
| Financials, segments, employees, debt | AbbVie FY2025 Form 10-K (filed Feb 2026; year ended Dec 31, 2025; consolidated statements, Note 1, segment disclosure) |
| Latest quarter (Q2 2026) | AbbVie Q2 2026 earnings release (July 31, 2026; quarter ended Jun 30, 2026) |
| Index weight & rank | Assignment baselines (SPX #20 · 0.71%) |
| Market cap & sector rank | Assignment baselines ($504B · #3 in Health Care) |
| History | 10-K Note 1 (incorporation, Abbott spin-off); 10-K shareholder and lead-director letters (leadership, Humira LOE, 2025 BD & approvals); AbbVie IR press releases (Pharmacyclics, Allergan, ImmunoGen, Cerevel, Aliada, Capstan, Apogee) |
| Dividend | AbbVie IR (Oct 31, 2025 dividend declaration); dividend history (stockanalysis.com, Oct 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | ABBV(NYSE) |
| 公司 | AbbVie Inc.(艾伯維) |
| GICS 板塊/行業 | 醫療健康(XLV)/生物科技 |
| 標普500排名(按權重) | #20 · 0.71%(任務基線) |
| 板塊內排名(按市值) | 醫療健康 #3(任務基線) |
| 總部 | 伊利諾州北芝加哥(1 North Waukegan Road) |
| 成立 | 2013年1月1日(自 Abbott Laboratories 分拆;2012年4月10日於德拉瓦州註冊成立) |
| 執行長 | Robert A. Michael(董事長兼執行長;2024年7月1日出任執行長,2025年7月1日出任董事長) |
| 員工 | 約57,000人,遍佈70多個國家(2025年12月31日,FY2025 10-K) |
| 市值 | $504B(5,040億美元)(任務基線) |
| SEC 申報 | EDGAR — CIK 0001551152 |
業務概覽
艾伯維是一家總部位於伊利諾州北芝加哥的全球生物製藥公司——用公司自己的話說,從事「針對全球最複雜、最嚴重疾病的廣泛療法的發現、開發、製造與銷售」(FY2025 10-K)。一句話商業模式:開發或收購有專利保護的品牌藥,再透過批發商、經銷商、政府機構與專科藥房銷往全球;醫美產品則直接銷售給醫師等執業醫療提供者。免疫學是引擎:FY2025 創紀錄的 $61.160B(611.6億美元)淨營收中,近一半來自免疫學產品組合。
艾伯維按單一全球業務板塊申報;管理層按治療領域討論營收。免疫學($30.406B(304.06億美元),同比 +14.0%)靠 Skyrizi($17.562B(175.62億美元),+49.9%)與 Rinvoq($8.304B(83.04億美元),+39.1%)接替 Humira($4.540B(45.4億美元),−49.5%)走下製藥史上最大專利懸崖。神經科學($10.767B(107.67億美元),+19.6%)是增長最快的治療領域:Vraylar($3.621B(36.21億美元))、Botox Therapeutic($3.769B(37.69億美元))、Ubrelvy($1.271B(12.71億美元))、Qulipta($1.036B(10.36億美元))與 Vyalev($482M(4.82億美元),2024年為 $99M(9,900萬美元))。腫瘤學($6.655B(66.55億美元),+1.5%)靠 Venclexta($2.792B(27.92億美元),+8.1%)抵銷 Imbruvica 的下滑($2.869B(28.69億美元),−14.3%),加上抗體藥物複合體 Elahere($690M(6.9億美元),+44.0%)。醫美($4.860B(48.6億美元),−6.1%)是 Botox Cosmetic($2.602B(26.02億美元))與 Juvederm 系列($993M(9.93億美元),−15.6%),受消費疲軟拖累。眼科($2.109B(21.09億美元),−5.9%)與其他重點產品($3.736B(37.36億美元),+2.4%——Creon $1.512B(15.12億美元)、Mavyret $1.317B(13.17億美元)、Linzess $907M(9.07億美元))構成其餘組合。
商業模式是在規模上跑專利懸崖跑步機:2025 年 GAAP 研發 $9.096B(90.96億美元),調整後研發投入 $13.8B(138億美元),另有逾 $5B(50億美元)的 2025 年業務開發(重度憂鬱症新型迷幻化合物、體內 CAR-T、siRNA 平台、肥胖症長效 amylin 類似物),在 Humira 衰退之際重建管線。2020 年收購 Allergan 把營收基礎多元化到醫美與眼科;ImmunoGen、Cerevel、Aliada、Capstan 等交易(以及 2026 年 6 月宣布的 $10.9B(109億美元)Apogee 收購)持續為腫瘤與神經科學管線供血。強勁的現金生成——2025 年營運現金流 $19.030B(190.3億美元)——支撐醫療健康業最長的股息連增紀錄之一(2025 年派息 $11.657B(116.57億美元))。
業務組合 — FY2025 淨營收(治療領域)
| 產品組合 | 淨營收 | 佔比 | 同比 | 重點產品 |
|---|---|---|---|---|
| 免疫學 | $30.406B(304.06億美元) | 49.7% | +14.0% | Skyrizi $17.56B(175.6億美元)· Rinvoq $8.30B(83億美元)· Humira $4.54B(45.4億美元) |
| 神經科學 | $10.767B(107.67億美元) | 17.6% | +19.6% | Vraylar $3.62B(36.2億美元)· Botox Therapeutic $3.77B(37.7億美元)· Ubrelvy $1.27B(12.7億美元)· Qulipta $1.04B(10.4億美元) |
| 腫瘤學 | $6.655B(66.55億美元) | 10.9% | +1.5% | Venclexta $2.79B(27.9億美元)· Imbruvica $2.87B(28.7億美元)· Elahere $0.69B(6.9億美元)· Epkinly $0.27B(2.7億美元) |
| 醫美 | $4.860B(48.6億美元) | 7.9% | −6.1% | Botox Cosmetic $2.60B(26億美元)· Juvederm 系列 $0.99B(9.9億美元) |
| 其他重點產品 | $3.736B(37.36億美元) | 6.1% | +2.4% | Creon $1.51B(15.1億美元)· Mavyret $1.32B(13.2億美元)· Linzess $0.91B(9.1億美元) |
| 眼科 | $2.109B(21.09億美元) | 3.4% | −5.9% | Ozurdex $0.49B(4.9億美元)· Lumigan/Ganfort $0.41B(4.1億美元) |
| 其他 | $2.627B(26.27億美元) | 4.3% | n/m | — |
| 淨營收合計 | $61.160B(611.6億美元) | 100% | +8.6% | — |
免疫學是後 Humira 時代的增長引擎。Skyrizi 與 Rinvoq 2025 年合計 $25.866B(258.66億美元),同比增加 $8.2B(82億美元);Humira 則從 2023 年的 $14.404B(144.04億美元)跌至 $4.540B(45.4億美元)。執行長 Robert Michael 指出,自失去專利保護以來美國 Humira 銷售侵蝕「接近 $16B(160億美元)」;公司目標 2027 年 Skyrizi/Rinvoq 合計銷售突破 $31B(310億美元)。
神經科學是增長最快的治療領域(+19.6%),以 Vraylar 與 Botox Therapeutic 為錨,偏頭痛雙藥 Ubrelvy/Qulipta(合計 $2.307B(23.07億美元))與帕金森新藥 Vyalev 接續。2024 年 $8.7B(87億美元)收購 Cerevel 加深神經科學管線;公司預期帕金森產品線(Vyalev 加 tavapadon)峰值銷售將超過 $5B(50億美元)。
腫瘤學處於換擋期:Venclexta(+8.1%)與 Elahere 抗體藥物複合體(+44.0%)增長,抵銷 Imbruvica(−14.3%,受 IRA 醫保議價與新一代 BTK 競爭衝擊)的下滑。2024 年 $10.1B(101億美元)收購 ImmunoGen 帶來 Elahere。
醫美與眼科是 Allergan 遺產——能產生現金但具週期性(醫美 −6.1%,消費疲軟)且面臨仿製藥壓力(眼科 −5.9%,主因 Restasis)。
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 2012 | 4月10日——AbbVie Inc. 於德拉瓦州註冊成立(FY2025 10-K 註1) |
| 2013 | 1月1日——自 Abbott Laboratories 分拆完成;艾伯維成為獨立上市公司,承接 Humira(FY2025 10-K 註1) |
| 2015 | 以 $21B(210億美元)收購 Pharmacyclics——帶來首個腫瘤重磅藥 Imbruvica(公司 IR) |
| 2019–20 | Allergan 收購宣布(2019年6月)並於 2020 年 5 月 8 日以 $63B(630億美元)完成——納入 Botox、Juvederm 系列與眼科產品線(公司 IR) |
| 2023 | Humira 在美國首遇生物類似藥競爭(1月)——「製藥史上最大專利懸崖」(10-K 致股東信);Humira 美國銷售開始陡峭下滑 |
| 2024 | ImmunoGen 收購完成(2月,$10.1B(101億美元))——Elahere 抗體藥物複合體;Cerevel Therapeutics 收購完成(8月,$8.7B(87億美元))——神經科學管線;Aliada Therapeutics 收購(12月,$1.4B(14億美元))——阿茲海默抗體 |
| 2024 | 7月1日——Robert A. Michael 出任執行長;Vyalev 獲 FDA 批准用於晚期帕金森病(10月) |
| 2025 | 重要獲批:Rinvoq 治巨細胞動脈炎、Emrelis(telisotuzumab vedotin)治非鱗狀非小細胞肺癌、Epkinly 治二線濾泡性淋巴瘤(10-K 致股東信);收購 Capstan Therapeutics($2.1B(21億美元))——體內 CAR-T 平台;以 $906M(9.06億美元)首付款收購 Gilgamesh 重度憂鬱症迷幻化合物 |
| 2025 | 7月1日——Michael 出任董事長;Rick Gonzalez 榮休執行董事長(10-K 獨立董事信) |
| 2026 | 6月22日(宣布)——收購 Apogee Therapeutics 最終協議,股權價值 $10.9B(109億美元),以長效生物製劑深化免疫學產品線;預計 2026 年第三季完成(2026 年第二季財報) |
競爭地位
財務快照 — FY2025
| 淨營收 | $61.160B(611.6億美元)(同比 +8.6% 申報口徑/+8.5% 固定匯率;FY2024 $56.334B(563.34億美元)) |
| 產品銷售成本 | $18.204B(182.04億美元)(同比 +7.7%) |
| 毛利/毛利率 | $42.956B(429.56億美元)/ 70.2%(由申報數字計算) |
| 銷售及管理費用 | $14.010B(140.1億美元)(同比 −5.0%) |
| 研發(GAAP) | $9.096B(90.96億美元)(同比 −28.9%;FY2024 含 Cerevel/ImmunoGen 大額費用) |
| 收購中研發與里程碑 | $5.016B(50.16億美元) |
| 營業利潤/營業利潤率 | $15.075B(150.75億美元)/ 24.6%(由申報數字計算) |
| 調整後研發投入(非GAAP) | $13.8B(138億美元)(10-K 致股東信) |
| 淨利潤 | $4.233B(42.33億美元)(歸屬艾伯維 $4.226B(42.26億美元));淨利率 6.9%(計算值) |
| 稀釋 EPS(GAAP) | $2.36(2.36美元)(FY2024 為 $2.39(2.39美元)) |
| 調整後稀釋 EPS(非GAAP) | $10.00(10美元)(同比 −1.2%;含每股 −$2.76(2.76美元)的收購中研發與里程碑費用) |
| 營運現金流 | $19.030B(190.3億美元) |
| 資本支出 | $1.214B(12.14億美元) |
| 自由現金流 | $17.816B(178.16億美元)(營運現金流 − 資本支出;計算值) |
| 總債務 | $64.997B(649.97億美元)(2025年12月31日長期債務與融資租賃) |
| 現金及等價物 | $5.229B(52.29億美元)(2025年12月31日) |
| 淨債務 | $59.768B(597.68億美元)(總債務 − 現金;計算值) |
| 已付股息 | $11.657B(116.57億美元);季股息上調 5.5% 至 $1.73(1.73美元)(2025年10月31日;2026年2月17日支付;年化 $6.92(6.92美元)) |
| 最新一季(2026 年第二季,截至6月30日) | 淨營收 $16.990B(169.9億美元)(同比 +10.2%)· GAAP 稀釋 EPS $2.03(2.03美元)(同比 +290.4%)· 調整後稀釋 EPS $3.65(3.65美元)(同比 +22.9%;含每股 −$0.17(0.17美元)研發費用)· 調整後毛利率 84.7% · 調整後營業利潤率 48.3% · 2026 年全年指引:淨營收約 $67.6B(676億美元),調整後稀釋 EPS $13.87–14.07(13.87–14.07美元)(含 $0.14(0.14美元)Apogee 稀釋) |
主要風險
對標普500的重要性
艾伯維是指數第 20 大成分股,權重 0.71%(任務基線)——ABBV 單獨波動 1%,標普500 大約動 0.7 個基點——也是醫療健康板塊市值第三名。它是指數中最純的大型生物科技風向標(GICS 子行業為生物科技,按任務基線),與 Johnson & Johnson、Eli Lilly、UnitedHealth 同為 XLV 的錨定權重之一。
對市場結構觀察者而言,ABBV 是三個主題的板塊讀數:史上最大專利懸崖之後的生物類似藥侵蝕速度(Humira)、新一代免疫生物製劑的定價權(Skyrizi/Rinvoq),以及 IRA 醫保藥品議價的實際衝擊(Imbruvica)。連續 54 年提高年度股息,它也是醫療健康板塊的收益錨——2025 年 $11.657B(116.57億美元)股息被 $17.8B(178億美元)自由現金流舒適覆蓋。
來源與方法
| 財務、產品組合、員工、債務 | 艾伯維 FY2025 Form 10-K(2026年2月申報;會計年度截至2025年12月31日;合併報表、註1、板塊披露) |
| 最新一季(2026 年第二季) | 艾伯維 2026 年第二季財報(2026年7月31日;季度截至2026年6月30日) |
| 指數權重與排名 | 任務基線(標普500 #20 · 0.71%) |
| 市值與板塊排名 | 任務基線($504B(5,040億美元)· 醫療健康 #3) |
| 歷史 | 10-K 註1(註冊成立、Abbott 分拆);10-K 致股東信與獨立董事信(領導層、Humira 專利懸崖、2025 年業務開發與獲批);艾伯維 IR 新聞稿(Pharmacyclics、Allergan、ImmunoGen、Cerevel、Aliada、Capstan、Apogee) |
| 股息 | 艾伯維 IR(2025年10月31日股息宣告);股息歷史(stockanalysis.com,2026年10月) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-24 10:15 · updated 2026-11-14 22:50 · rev 11